Potential role of regulatory DNA variants in modifying the risk of severe cutaneous reactions induced by aromatic anti-seizure medications.
Kerry A MullanAlison AndersonYi-Wu ShiJia-Hong DingChing-Ching NgZhibin ChenLarry BaumStacey ChernySlave PetrovskiPak C ShamKheng-Seang LimWei-Ping LiaoPatrick KwanPublished in: Epilepsia (2022)
We identified variants that could explain why some carriers of HLA-B*15:02 tolerate treatment, and why some noncarriers develop ASM-induced SJS/TEN. Additionally, this analysis suggests that the mixing of HLA-B*15:02 carrier status in previous studies might have masked variants contributing to susceptibility, and that inheritance of risk for ASM-induced SJS/TEN is complex, likely involving multiple risk variants.